358 related articles for article (PubMed ID: 37247045)
1. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
[TBL] [Abstract][Full Text] [Related]
2. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
3. Time-trends in disease characteristics and comorbidities in patients with chronic hepatitis B in the period 1980-2020.
van der Spek DPC; Katwaroe WK; van Kleef LA; Brakenhoff S; de Man RA; de Knegt RJ; van der Meer AJ; Sonneveld MJ
Eur J Intern Med; 2023 Jan; 107():86-92. PubMed ID: 36396524
[TBL] [Abstract][Full Text] [Related]
4. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Li B; Cheung KS; Yuen MF; Seto WK
Hepatol Int; 2021 Aug; 15(4):901-911. PubMed ID: 34152534
[TBL] [Abstract][Full Text] [Related]
5. Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.
Yu MW; Lin CL; Liu CJ; Wu WJ; Hu JT; Huang YW
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497492
[TBL] [Abstract][Full Text] [Related]
6. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
Kim MN; Han K; Yoo J; Hwang SG; Zhang X; Ahn SH
Int J Cancer; 2023 Oct; 153(8):1448-1458. PubMed ID: 37439276
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].
Shang MY; Chen YZ; Bao J; Tong YL
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):126-132. PubMed ID: 37137826
[No Abstract] [Full Text] [Related]
8. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B.
Lee YB; Ha Y; Chon YE; Kim MN; Lee JH; Park H; Kim KI; Kim SH; Rim KS; Hwang SG
Clin Mol Hepatol; 2019 Mar; 25(1):52-64. PubMed ID: 30360031
[TBL] [Abstract][Full Text] [Related]
9. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
[TBL] [Abstract][Full Text] [Related]
10. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study.
Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
Hepatol Res; 2022 Dec; 52(12):975-984. PubMed ID: 35976670
[TBL] [Abstract][Full Text] [Related]
11. Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B.
Cho H; Chang Y; Lee JH; Cho YY; Nam JY; Lee YB; Lee DH; Cho EJ; Yu SJ; Kim YJ; Lee JM; Yoon JH
J Clin Gastroenterol; 2020 Aug; 54(7):633-641. PubMed ID: 31033805
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of clinical characteristics and risk factors of hepatic fibrosis in children with chronic hepatitis B combined with metabolic-related fatty liver disease].
Li W; Jiang LN; Zhao BK; Liu HY; Zhao JM
Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):601-607. PubMed ID: 37400384
[No Abstract] [Full Text] [Related]
13. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives.
Huang SC; Liu CJ
Clin Mol Hepatol; 2023 Apr; 29(2):320-331. PubMed ID: 36726053
[TBL] [Abstract][Full Text] [Related]
14. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis.
Wong YJ; Nguyen VH; Yang HI; Li J; Le MH; Wu WJ; Han NX; Fong KY; Chen E; Wong C; Rui F; Xu X; Xue Q; Hu XY; Leow WQ; Goh GB; Cheung R; Wong G; Wong VW; Yu MW; Nguyen MH
Clin Mol Hepatol; 2023 Jul; 29(3):705-720. PubMed ID: 37157776
[TBL] [Abstract][Full Text] [Related]
15. Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B.
Huang SC; Kao JH
J Formos Med Assoc; 2022 Nov; 121(11):2148-2151. PubMed ID: 35981929
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
17. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Cheung KS; Yuen MF; Seto WK
J Hepatol; 2020 Oct; 73(4):800-806. PubMed ID: 32504663
[TBL] [Abstract][Full Text] [Related]
18. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.
Lee J; Yoo SH; Sohn W; Kim HW; Choi YS; Won JH; Heo JY; Park SJ; Park YM
Clin Mol Hepatol; 2016 Sep; 22(3):339-349. PubMed ID: 27729627
[TBL] [Abstract][Full Text] [Related]
19. Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of Cirrhosis in Patients with Chronic Hepatitis B-A Retrospective Cohort Study.
Wang QX; Xue J; Shi MJ; Xie YB; Xiao HM; Li S; Lin M; Chi XL
Diabetes Metab Syndr Obes; 2022; 15():2311-2322. PubMed ID: 35942038
[TBL] [Abstract][Full Text] [Related]
20. Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors.
Yu MW; Lin CL; Liu CJ; Huang YW; Hu JT; Wu WJ; Wu CF
J Formos Med Assoc; 2022 Aug; 121(8):1478-1487. PubMed ID: 34764005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]